Cargando…

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design

INTRODUCTION: We investigated the influence of different inclusion criteria for preclinical and prodromal Alzheimer's disease (AD) on changes in biomarkers and cognitive markers and on trial sample size estimates. METHODS: We selected 522 cognitively normal subjects and 872 subjects with mild c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertens, Daniela, Tijms, Betty M., Vermunt, Lisa, Prins, Niels D., Scheltens, Philip, Visser, Pieter Jelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671625/ https://www.ncbi.nlm.nih.gov/pubmed/29124109 http://dx.doi.org/10.1016/j.trci.2017.08.005

Ejemplares similares

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Complementary pre‐screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project
por: Boada, Mercè, et al.
Publicado: (2021)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Onset of Preclinical Alzheimer Disease in Monozygotic Twins
por: Konijnenberg, Elles, et al.
Publicado: (2021)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
por: Jutten, Roos J., et al.
Publicado: (2021)

Can novel therapeutics halt the amyloid cascade?
por: Prins, Niels D, et al.
Publicado: (2010)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
por: Bertens, Daniela, et al.
Publicado: (2019)

Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET
por: López-de-Eguileta, Alicia, et al.
Publicado: (2019)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease
por: Nakamura, Akinori, et al.
Publicado: (2018)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
por: Soininen, Hilkka, et al.
Publicado: (2020)

Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
por: Startin, Carla M., et al.
Publicado: (2019)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Plasma proteins predict conversion to dementia from prodromal disease
por: Hye, Abdul, et al.
Publicado: (2014)

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials
por: Borland, Emma, et al.
Publicado: (2022)

Neuropsychological assessment in preclinical and prodromal Alzheimer disease: a global perspective
por: Watermeyer, Tamlyn, et al.
Publicado: (2019)

The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
por: Morrison, Cassandra, et al.
Publicado: (2023)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Prevalence and persistence of smell and taste dysfunction in COVID-19; how should dental practices apply diagnostic criteria?
por: Hopkins, Claire, et al.
Publicado: (2021)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial
por: Rosenberg, Anna, et al.
Publicado: (2021)

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5
por: Papp, Kathryn V., et al.
Publicado: (2017)

Cognitive and physical markers of prodromal dementia: A 12‐year‐long population study
por: Grande, Giulia, et al.
Publicado: (2020)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome
por: Hartley, Sigan L., et al.
Publicado: (2020)

Sleep and Tau Pathology in Vietnam War Veterans with Preclinical and Prodromal Alzheimer’s Disease
por: Andrews, Murray, et al.
Publicado: (2021)

MRI-based Alzheimer’s disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer’s disease
por: Liu, Wanting, et al.
Publicado: (2021)

Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
por: Prins, Niels D, et al.
Publicado: (2013)

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
por: Zhou, Yan, et al.
Publicado: (2016)

Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers
por: Weiner, Sophia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_edk3v02foeeaca9on4942ecmr8